Current stage-Stage II (Early) Posts on Medivizor
Navigation Menu

Current stage-Stage II (Early) Posts on Medivizor

Does radiotherapy reduce the risk of recurrence in patients with early-stage Hodgkin lymphoma?

Does radiotherapy reduce the risk of recurrence in patients with early-stage Hodgkin lymphoma?

Posted by on Sep 12, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study looked at whether radiotherapy had an impact on the recurrence rate in patients with early-stage Hodgkin lymphoma (HL). It found that in patients with early-stage HL who responded fully to chemotherapy, the addition of radiotherapy reduced the risk of localized recurrence.  Some background Early-stage...

Read More

Is PET-guided exclusion of radiotherapy an appropriate treatment regimen for unfavorable early-stage Hodgkin lymphoma?

Is PET-guided exclusion of radiotherapy an appropriate treatment regimen for unfavorable early-stage Hodgkin lymphoma?

Posted by on Mar 21, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell The authors investigated the impact of removing radiotherapy (RT) from treatment regimens in patients with early-stage unfavorable Hodgkin lymphoma (HL). This study concluded that this treatment regimen is just as effective as the standard of care.  Some background Chemotherapy and consolidation RT is the standard of care for...

Read More

Does first-line treatment with R-CHOP benefit patients with grade 3A follicular lymphoma?

Does first-line treatment with R-CHOP benefit patients with grade 3A follicular lymphoma?

Posted by on Aug 30, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to compare the effectiveness of 2 drug regimens for patients with grade 3A follicular lymphoma (FL3A). The authors concluded that R-CHOP has a benefit over RB in the treatment of these patients. Some background Follicular lymphoma (FL) is the most common type of non-Hodgkin lymphoma (NHL).FL usually has good...

Read More

Stanford V chemotherapy and limited filed irradiation for patients with unfavorable risk stage I-II classic Hodgkin lymphoma

Stanford V chemotherapy and limited filed irradiation for patients with unfavorable risk stage I-II classic Hodgkin lymphoma

Posted by on Jul 19, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate the long-term outcomes for patients with stage I-II classic Hodgkin lymphoma and unfavorable risk who were treated with Stanford V combined modality therapy.  This study concluded that the long-term outcomes for these patients were favorable and comparable to other standard...

Read More

Managing patients with limited-stage Hodgkin lymphoma by brentuximab vedotin based therapy

Managing patients with limited-stage Hodgkin lymphoma by brentuximab vedotin based therapy

Posted by on Jul 5, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell The study evaluated if brentuximab-vedotin (BV; Adcetris) consolidation therapy can reduce the use of radiation therapy (RT) in patients with limited-stage (LS) Hodgkin lymphoma (HL). The authors found that BV consolidation achieved good outcomes in such patients when given after ABVD therapy. Some background HL is a cancer of the...

Read More

10 year outcomes of early-stage Hodgkin lymphoma

Posted by on Apr 14, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study looked at long-term outcomes of patients with early-stage Hodgkin lymphoma according to different treatments. It found that patients who received both radiation and chemotherapy had improved long-term survival compared to either treatment alone. Some background At present, over 90% of patients with classical Hodgkin lymphoma...

Read More

Can PET scanning help guide treatment for patients with Hodgkin’s lymphoma?

Posted by on Oct 13, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated whether PET scanning after chemotherapy might help predict outcomes and guide treatment for patients with early-stage Hodgkin's lymphoma (HL). This study found that PET scanning can help identify high-risk patients after chemotherapy. Some background Chemotherapy combined with radiotherapy is the standard of...

Read More

Looking for patients with aggressive B-cell NHL to try an experimental combination treatment

Posted by on Sep 30, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study is investigating how well nivolumab (Opdivo) works with DA-REPOCH chemotherapy for treating aggressive B-cell non-Hodgkin's lymphoma (NHL). The primary outcome to be measured is 2-year survival without disease progression after treatment. This study is being conducted in Columbus, OH, in the United States. The...

Read More

Evaluating A+AVD chemotherapy for patients with early-stage Hodgkin lymphoma

Posted by on Jul 8, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of a modified chemotherapy regimen for patients with early-stage Hodgkin lymphoma (HL). This study concluded that this regimen was effective but associated with more side effects. Some background The most commonly used frontline chemotherapy regimen for HL is ABVD (doxorubicin,...

Read More

PET scanning for predicting outcomes for early-stage Hodgkin lymphoma

Posted by on Jun 16, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study assessed the usefulness of PET scanning in determining outcomes for patients with early-stage Hodgkin lymphoma (HL). This study concluded that PET scanning after chemotherapy was strongly associated with patient outcomes in early-stage HL. Some background For patients with HL, the goal of treatment is to improve outcomes...

Read More

Searching for patients with relapsed or unresponsive follicular lymphoma to trial a new drug

Posted by on Apr 24, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This trial will evaluate the effects of a new treatment parsaclisib (INCB050465) in relapsed or unresponsive follicular lymphoma (FL). Response rate, survival, and side effects will be the main outcomes measured. The details Many patients are cured with treatments for follicular lymphoma (FL). Some, however, lose response to therapy...

Read More